Myriad Genetics obtains $300 million five-year revolving facility

By Wendy Van Sickle

Columbus, Ohio, Dec. 28 – Myriad Genetics, Inc. entered into a $300 million senior secured revolving credit facility on Friday, according to an 8-K filing with the Securities and Exchange Commission.

JPMorgan Chase Bank, NA is administrative agent; Wells Fargo Bank, NA is syndication agent; and U.S. Bank NA, PNC Bank, NA, Fifth Third Bank, Zions First National Bank, NA and Silicon Valley Bank are the co-documentation agents.

The revolver matures on Dec. 23, 2021. It has $10 million sublimits for swingline loans and letters of credit.

At closing, Myriad borrowed $205 million, which it used to refinance its term loan facility entered into on Aug. 31, to pay related expenses and for working capital and general corporate purposes.

Myriad is a Salt Lake City-based personalized medicine company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.